COVID-19 Tag

Pharma is facing the many challenges of COVID-19 head-on. Leading organizations are taking full advantage of today’s sophisticated analytic tools, including state-of-the-art anonymization technologies that seamlessly link patient data across multiple sources, to monitor the impact of COVID-19 on treatments in new ways.   Since the COVID-19 pandemic began, the industry has been primarily focused on understanding the journey of severely ill, older adults requiring hospitalization. More...

Read More

Did you know that 70% of medical diagnosis are informed by clinical lab results data?   Over the past five months, round-the-clock news reports have kept us well informed of data related to patients testing positive for COVID-19. People everywhere have been closely following this data in an attempt to gauge – and hopefully control – the impact of the virus.   Critical insights about the patient journey can,...

Read More

MSA’s Healthcare Data Management experts provide solutions that empower pharma to better understand the impact of COVID-19 on the diabetes patient journey by linking clinical lab results, prescriptions, EMR, and medical claims data – all while protecting patient privacy. MSA, provider of the industry’s most credentialed, configurable, and trusted de-identification and data management solutions, accurately anonymizes and seamlessly links disparate data from one or multiple...

Read More

A close examination of the COVID-19 patient journey will result in a better understanding of the impact of the virus on at-risk diabetes patients. Segmenting positive and negative COVID-19 patients provides a real world comparison of anonymized patient cohorts’ A1C, fasting blood sugars, and glucose levels. Linked with prescribed medications, this data will identify the impact of COVID-19 on the patients’ prescribed drug therapy. The...

Read More